Javelin Advisory Group

The Javelin offices remain very busy with the work in support of its clients, all of which have been involved in a great deal of activity over the past several months. Some of this client activity, such as that of Green Globe International, is readily apparent through the press releases that have been issued during the period. Other companies, such as CLX Medical, have been relatively quiet for a period, but recently CLX has issued a number of extremely significant news items, which we expect to impact the long-term prospects for the company. In the case of ActionView International, the majority of the recent activity involving the future of the company has occurred behind the scenes, but that, too, is expected to change in the coming weeks. We hope that investors that follow the progress of Javelin clients have been monitoring the news and will look for the follow-up announcements and tangible progress that we expect to result from the recent news.

In the case of Green Globe International, the company was pleased to report its first contract to deliver sustainability services to the Estoril Congress Center in Portugal. While we do not expect every payment to the company to be reported in a press release, as this was the first since our the acquisition of the Green Globe brand was completed, it was important to report the first revenues delivered to the company. The worldwide opportunities for Green Globe are becoming more apparent every day, and we expect there to be more highly impactful announcements to be made in the near term as evidence of these opportunities.

CLX Medical has announced ThyroTest® as the FDA approved and CLIA waived product it has targeted for acquisition, as well as LETI Laboratories of Spain as the Master Distributor it has selected for the European market. The acquisition of ThyroTest® puts CLX in position to establish distribution for the device in the U.S. and worldwide markets. CLX will also continue to complete the work necessary to achieve FDA clearance and CLIA waiver for Zonda’s chlamydia test.

Both Green Globe and CLX are now positioned to improve their status in the public markets, and Javelin is going to take a prominent role in supporting the advancement of both of these companies. We hope to be able to expand on this topic and we will look for every opportunity to provide specifics whenever possible.

On separate topic, blog readers may have seen a recent press release reporting that Javelin Advisory Group was named in a derivative lawsuit filed by Krause Kalfayan Benink & Slavens, LLP. The suit involves Unico, Incorporated, a company that Javelin worked with several years ago. While Javelin has not been served with any papers concerning the suit, we do not believe that the services we provided for Unico will cause any exposure in this matter.